Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

Company Overview

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders. The company leverages strategic partnerships for manufacturing and formulation development while pursuing regulatory approvals in key markets. Its clinical trial activities span North America and Europe, with trial sites designed to support potential future commercialization in regions where NASH represents a substantial unmet medical need.

Founded in 2001 and headquartered in Tel Aviv, Israel, Galmed maintains corporate offices in the United States to facilitate interactions with regulatory agencies, clinical investigators and potential commercial partners. The company’s leadership team combines expertise in pharmaceutical development, hepatology and global commercialization strategy. Galmed Pharmaceuticals is publicly traded on the NASDAQ under the ticker symbol GLMD and remains committed to advancing therapies for patients suffering from progressive liver disease.

Key Stats

• Today's Range: $1.51 to $1.60
• 50-Day Range: $1.27 to $1.63
• 52-Week Range: $1.15 to $4.81
• Volume: 55,119 shs
• Average Volume: 904,831 shs
• Market Capitalization: $2.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Galmed Pharmaceuticals Stock Analysis - MarketRank™

Galmed Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Galmed Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Galmed Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Galmed Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Galmed Pharmaceuticals has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.82% of the float of Galmed Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galmed Pharmaceuticals has recently decreased by 39.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galmed Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Galmed Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.82% of the float of Galmed Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galmed Pharmaceuticals has recently decreased by 39.22%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.63

News Sentiment

Galmed Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Galmed Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for GLMD on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GLMD Stock Analysis - Frequently Asked Questions

How have GLMD shares performed this year?

Galmed Pharmaceuticals' stock was trading at $3.19 on January 1st, 2025. Since then, GLMD shares have decreased by 52.8% and is now trading at $1.5050.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) posted its quarterly earnings results on Thursday, May, 22nd. The biopharmaceutical company reported ($0.62) EPS for the quarter.

When did Galmed Pharmaceuticals' stock split?

Galmed Pharmaceuticals's stock reverse split on the morning of Monday, May 15th 2023.The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include Viking Therapeutics (VKTX), OPKO Health (OPK), SCYNEXIS (SCYX), Bristol Myers Squibb (BMY), Plug Power (PLUG), Applied Genetic Technologies (AGTC) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 5/22/2025
• Today: 10/09/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLMD
• CIK: 1595353
• Web: www.galmedpharma.com
• Phone: (723) 693-8448
• Fax: 972-3693-8447
• Employees: 20
• Year Founded: 2000

Profitability

• EPS (Trailing Twelve Months): ($16.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.69%
• Return on Assets: -18.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.71
• Quick Ratio: 8.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.87 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 1,654,000
• Free Float: 1,327,000
• Market Cap: $2.57 million
• Optionable: Not Optionable
• Beta: 0.50